Ligand Announces Multi-Program LTP Technology Licensing Agreement with Nucorion Pharmaceuticals
Ligand Pharmaceuticals Incorporated announces the signing of a license agreement for three programs utilizing Ligand’s LTP (Liver Targeting Prodrug) technology with Nucorion…
Read More...
Read More...